European Union · Question · QUESTION_WRITTEN
E-9-2021-001655
Pharmacovigilance strategy on the AstraZeneca vaccine and recent statements from the National Institute of Allergy and Infectious Diseases
Introduced
24 March 2021
Last action
—
Status
answered
Sponsors
—
Subjects
Discovery layer
Source updated
31 May 2021
Records
Official question E-9-2021-001655 from European Union at European Parliament. Dated 24 March 2021. Status: answered.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
7 official files
Pharmacovigilance strategy concerning the AstraZeneca vaccine and recent statements by the National Institute of Allergy and Infectious Diseases (NIAID)
QUESTION_WRITTEN · EN · 12 April 2021
Pharmacovigilance strategy concerning the AstraZeneca vaccine and recent statements by the National Institute of Allergy and Infectious Diseases (NIAID)
QUESTION_WRITTEN · EN · 12 April 2021
Pharmacovigilance strategy concerning the AstraZeneca vaccine and recent statements by the National Institute of Allergy and Infectious Diseases (NIAID)
QUESTION_WRITTEN · EN · 12 April 2021
Answer
QUESTION_WRITTEN_ANSWER · 31 May 2021
Strategia di farmacovigilanza sul vaccino AstraZeneca e recenti dichiarazioni del National Institute of Allergy and Infectious Diseases
QUESTION_WRITTEN · IT · 12 April 2021
Strategia di farmacovigilanza sul vaccino AstraZeneca e recenti dichiarazioni del National Institute of Allergy and Infectious Diseases
QUESTION_WRITTEN · IT · 12 April 2021
Strategia di farmacovigilanza sul vaccino AstraZeneca e recenti dichiarazioni del National Institute of Allergy and Infectious Diseases
QUESTION_WRITTEN · IT · 12 April 2021
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.